Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 9;80(3):339–348. doi: 10.1136/annrheumdis-2020-218599

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Adjusted mean change from baseline over time for selected biomarkers to day 365: (A) IgG, (B) IgA, (C) IgM-RF, (D) kappa light chain, (E) C4 complement and (F) CXCL13. P values were nominal. Adjusted mean differences at day 365 are versus the placebo arm switched to abatacept (rather than vs placebo). Biomarker assessments up to 56 days post-dose are included. Estimates of adjusted mean change are from a repeated measure mixed model that includes baseline biomarker result, treatment group, randomisation stratification factors (baseline oral corticosteroid use [yes/no], baseline hydroxychloroquine use [yes/no]), time, time-by-treatment group interaction and time-by-baseline biomarker result interaction. Baseline values were based on those patients included at day 29 (day 85 for CXCL13). *Units are calibrated against standard curves derived from a WHO international reference. CXCL13, chemokine ligand 13; RF, rheumatoid factor.